Background Psoriasis is a chronic, inflammatory skin disorder that has a significant impact on quality of life and, particularly in moderate to severe cases, adversely affects the patient's overall health and well-being. Biological treatments, such as etanercept, are being widely adopted across Europe for treatment of moderate to severe psoriasis due to favourable safety and efficacy profiles. The increase in usage, combined with a growing body of clinical evidence, has identified a need to clarify the best use of etanercept within its current treatment label. Objective To prepare a series of recommendations agreed by an expert group of dermatologists, relating to the most effective use of etanercept for psoriasis in Europe, within the product license. Methods An expert panel of dermatologists from across Europe completed a Delphi survey to address the current use of etanercept in psoriasis in Europe. In June 2005 the results were presented to the expert panel at their nominal group meeting, and a consensus was agreed. Results It was recommended that, where possible, patients are initiated on the 50 mg twice-weekly (BIW) dose. Etanercept should be given until remission is achieved (maximum 24 weeks) and retreatment should be initiated according to the physician's judgement. Before commencing treatment, contraindications, such as infection or previous malignancy (within 5 years), should be ruled out. Conclusions The consensus presented herein provides valuable clarification of use of etanercept according to the label, which may have wider implications relating to the use of all biological therapies in psoriasis.

Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus / W. H., Boehncke; R. A., Brasie; J., Barker; S., Chimenti; E., Dauden; M., de Rie; L., Dubertret; Giannetti, Alberto; A., Katsambas; K., Kragballe; J. M., Naeyaert; J. P., Ortonne; J., Peyri; J. C., Prinz; J. H., Saurat; R., Strohal; P., van de Kerkhof; W., Sterry. - In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. - ISSN 0926-9959. - STAMPA. - 20:8(2006), pp. 988-998. [10.1111/j.1468-3083.2006.01707.x]

Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus

GIANNETTI, Alberto;
2006

Abstract

Background Psoriasis is a chronic, inflammatory skin disorder that has a significant impact on quality of life and, particularly in moderate to severe cases, adversely affects the patient's overall health and well-being. Biological treatments, such as etanercept, are being widely adopted across Europe for treatment of moderate to severe psoriasis due to favourable safety and efficacy profiles. The increase in usage, combined with a growing body of clinical evidence, has identified a need to clarify the best use of etanercept within its current treatment label. Objective To prepare a series of recommendations agreed by an expert group of dermatologists, relating to the most effective use of etanercept for psoriasis in Europe, within the product license. Methods An expert panel of dermatologists from across Europe completed a Delphi survey to address the current use of etanercept in psoriasis in Europe. In June 2005 the results were presented to the expert panel at their nominal group meeting, and a consensus was agreed. Results It was recommended that, where possible, patients are initiated on the 50 mg twice-weekly (BIW) dose. Etanercept should be given until remission is achieved (maximum 24 weeks) and retreatment should be initiated according to the physician's judgement. Before commencing treatment, contraindications, such as infection or previous malignancy (within 5 years), should be ruled out. Conclusions The consensus presented herein provides valuable clarification of use of etanercept according to the label, which may have wider implications relating to the use of all biological therapies in psoriasis.
2006
20
8
988
998
Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus / W. H., Boehncke; R. A., Brasie; J., Barker; S., Chimenti; E., Dauden; M., de Rie; L., Dubertret; Giannetti, Alberto; A., Katsambas; K., Kragballe; J. M., Naeyaert; J. P., Ortonne; J., Peyri; J. C., Prinz; J. H., Saurat; R., Strohal; P., van de Kerkhof; W., Sterry. - In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. - ISSN 0926-9959. - STAMPA. - 20:8(2006), pp. 988-998. [10.1111/j.1468-3083.2006.01707.x]
W. H., Boehncke; R. A., Brasie; J., Barker; S., Chimenti; E., Dauden; M., de Rie; L., Dubertret; Giannetti, Alberto; A., Katsambas; K., Kragballe; J. M., Naeyaert; J. P., Ortonne; J., Peyri; J. C., Prinz; J. H., Saurat; R., Strohal; P., van de Kerkhof; W., Sterry
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/611873
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 34
social impact